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SAMHD1 is a deoxynucleotide triphosphohydrolase (dNTPase) which 
inhibits retroviruses by depleting intracellular deoxynucleotide triphosphates 
(dNTPs) in noncycling myeloid cells. Although SAMHD1 is expressed 
ubiquitously throughout the human body, the molecular mechanism to 
directly regulate its enzymatic activity and its function in non-immune cells 
are relatively unexplored. Here, I demonstrate that the dNTPase activity of 
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SAMHD1 is regulated by acetylation, which promotes cell cycle progression 
in cancer cells. SAMHD1 was acetylated at residue K405 by ARD1, an 
acetyltransferase, which directly enhanced its dNTPase activity in vitro. 
When SAMHD1 wildtype and non-acetylated K405R mutant overexpressing 
stable cells were constructed in cancer cells, K405R mutant expressing cells 
showed decreased G1/S transition and slower proliferation over wildtype 
cells. SAMHD1 acetylation level was strongest during the G1 phase, 
implicating its role during G1 phase. Collectively, these findings suggest that 
SAMHD1 acetylation enhances its dNTPase activity and promotes cancer 
cell proliferation.










LIST OF TABLES……………………………………….. xii





SAMHD1 is a 
dNTPase….………………………………………
6
2. SAMHD1 and innate immunity………..……………………….. 10
3. SAMHD1 and cell growth …………………..…………………. 13
iv






2. ARD1 is an acetyltransferase……………...…………………… 21
3. ARD1 is oncogenic……………………………………………... 23
PURPOSE OF THIS 
STUDY……………………………
25
MATERIALS AND METHODS………………………... 27
1.








in vitro acetylation 
assay………………………………………………………
28
4. Mass spectrometric analysis………………………………………………… 28
5.


















11. Protein sequence alignment………………………………………………… 34
12. Flow cytometry analysis……………………………………………………… 34
13. Cell proliferation assay……………………………………………………… 34
14. Colony formation assay……………………………………………………… 35
15. Fluorescence microscopy…………………………………………………… 35
16. Statistical analysis……………………………………………………………… 36
RESULTS ………………………………………………... 37
1.
S A M H D  i s  a  n o v e l  a c e t y l a t i o n  s u b s t r a t e  o f 
A R D 1 … … … … … …
37
2.
K 4 0 5  r e s i d u e  o f  S A M H D 1  i s  a c e t y l a t e d  b y 
A R D 1 … … … … … …
45
3. ARD1-mediated SAMHD1 acetylation enhances its dNTPase 
activity………………………………………………………… 56
4. SAMHD1 acetylation is important for cell proliferation in 
vi
v a r i o u s  c a n c e r  c e l l s 
… … … … … … … … … … … … … … … … … … … … …
64
5. SAMHD1 acetylation promotes G1/S transition in cancer
cells……………………………………………………………… 77
6. SAMHD1 acetylation may play other undiscovered roles in 
v a r i o u s  c e l l  l i n e s 






















RNR and de novo dNTP 
biosynthesis…………………………
5
Figure 4. Representative schematic or the important domains of 
SAMHD1……………………………………………………
8
Figure 5. Schematic illustration of the mechanism of SAMHD1 
activation by dGTP-induced tetramerization…………………
9
Figure 6. Effect of SAMHD1 on HIV-1 replication…………………… 11
Figure 7. SAMHD1 expression change during cell proliferation……… 14
viii
Figure 8. Model for the regulation of SAMHD1 restriction activity by   
phosphorylation at the Thr592 residue………………………
16
Figure 9.
Comparison of two types of protein 
acetylation………………
20
Figure 10. Schematics for functional switch of Hsp70 regulated by 
ARD1- mediated acetylation………………………………… 2
Figure 11. Schematic diagram showing the contribution of ARD1 in cell       
cycle progression…………………………………………… 24
Figure 12. LC-MS/MS analysis reveals SAMHD1 as a novel binding 
partner of ARD1……………………………………………… 40
Figure 13. Co-immunoprecipitation of endogenous SAMHD1 and 
FLAG-ARD1………………………………………………… 41
Figure 14. Recombinant SAMHD1 protein is acetylated by ARD1 in 
vitro………………………………………………………… 42
Figure 15. Endogenous SAMHD1 protein is acetylated by ARD1 in vivo 43
Figure 16. Endogenous SAMHD1 protein is less acetylated by ARD1 
mutants     in vivo………………………………………… 44
Figure 17. Construction of SAMHD1 deletion mutants………………… 48
Figure 18. Recombinant CTD protein of SAMHD1 was mainly 
acetylated by ARD1 in vitro………………………………… 49
Figure 19. Acetylated sites of GST-SAMHD1 CTD…………………… 50
ix
Figure 20. K405 is the major site of ARD1-mediated acetylation of 
SAMHD1 in vitro…………………………………………… 52
Figure 21. K405 is the major site of ARD1-mediated acetylation of 
SAMHD in vivo……………………………………………… 53
Figure 22. Sequence alignment of SAMHD1 K405 residue in various 
species……………………………………………………… 54
Figure 23. Location of K405 residue in SAMHD1 structure…………… 55
Figure 24. Schematic representation of in vitro dNTPase assay………… 58
Figure 25.




SAMHD1 K405R mutant does not show upregulated 
dNTPase activity in the presence of ARD1 in 
vitro……………………
60
Figure 27. SAMHD1 WT shows stronger dNTPase activity of K405R 
mutant in vivo………………………………………………… 61
Figure 28.
SAMHD1 WT shows stronger dNTPase activity in the 








Figure 30. Establishment of SAMHD1-downregulated cancer cells…… 68
Figure 31. Relative cell growth of SAMHD1-downregulated HeLa cells 69
x
Figure 32. SAMHD1-downregulated MCF7 cells show decreased 
anchorage-dependent colony formation……………………… 70
Figure 33. Establishment of FLAG-SAMHD1 WT or K405R 
overexpressing   stable cancer cell lines…………………… 71
Figure 34. Relative cell growth of FLAG-SAMHD1 WT or K405R 
overexpressing HeLa cells…………………………………… 72
Figure 35.
Anchorage-dependent colony formation of FLAG-SAMHD1 
expressing stable MCF7 
cells…………………………………
73
Figure 36. Anchorage-dependent colony formation of FLAG-SAMHD1 
expressing stable A549 cells………………………………… 74
Figure 37. Anchorage-dependent colony formation of FLAG-SAMHD1 
expressing stable Hep3B cells……………………………… 75
Figure 38. Anchorage-independent colony formation of FLAG-
SAMHD1 expressing stable HeLa cells……………………… 76
Figure 39. Cell cycle profiles of SAMHD1-downregulated HeLa cells… 81
Figure 40. Expression levels of cyclins in SAMHD1-downregulated 
HeLa cells…………………………………………………… 82
Figure 41. Cell cycle profiles of FLAG-SAMHD1 expressing stable 
A549 cells…………………………………………………… 83
Figure 42. Expression levels of cyclins in FLAG-SAMHD1 
overexpressing stable A549 cells…………………………… 84
xi
Figure 43. PCNA expression of FLAG-SAMHD1 overexpressing stable 
Hep3B cells………………………………………………… 85
Figure 44. SAMHD1 acetylation levels during cell cycle progression of 
FLAG-SAMHD1 overexpressing stable A549 cells………… 87
Figure 45. SAMHD1 acetylation levels during cell cycle progression of 
FLAG-SAMHD1 overexpressing stable HeLa cells………… 88
Figure 46. Expression levels of endogenous SAMHD1 during cell cycle 
progression of HeLa cells…………………………………… 89
Figure 47.
Expression levels of endogenous SAMHD1 during cell cycle 
progression of Hep3B 
cells……………………………………
90
Figure 48. Expression levels of endogenous SAMHD1 during cell cycle 
progression of A549 cells…………………………………… 91
Figure 49. Expression levels of endogenous SAMHD1 during cell cycle 
progression of MCF7 cells…………………………………… 92
Figure 50. SAMHD1 acetylation does not alter SAMHD1-cyclin A2 
binding……………………………………………………… 93
Figure 51. Physiological conditions of SAMHD1 acetylation in THP-1 
cells………………………………………………………… 96
Figure 52. Relationship between SAMHD1 and autophagy…………… 99
Figure 53. SAMHD1 acetylation alters the expression of junction 
proteins in various cancer cells……………………………… 102
xii
Figure 54. Schematic for the mechanism of ARD1-mediated SAMHD1 
acetylation in cancer cell proliferation……………………… 107
LIST OF TABLES






ARD1 Arrest defective 1
xiv
CDK1 Cyclin-dependent kinase 1
CTD C-terminal domain
dATP Deoxyadenosine triphosphate







HIV-1 human immunodeficiency virus-1
HSP70 Heat shock protein 70
IFNβ-2a Interferon β-2a
NAT Nα-terminal acetyltransferases





Runx2 Runt-related transcription factor 2
SAM Sterile alpha motif




Deoxyribonucleotide triphosphate (dNTP) is a molecule which contains a 
phosphate group, a deoxyribose sugar and a nitrogenous base (Figure 1). 4 
types of dNTPs exist depending on the nitrogenous base they contain; dATP, 
(deoxyadenosine triphosphate), and dGTP, (deoxyguanine triphosphate),
dTTP, (deoxythymidine triphosphate), and dCTP, (deoxycytidine 
triphosphate). They are necessary for life, as they are the precursors of DNA 
synthesis. According to base pairing rules (A with T, and C with G), the 
nitrogenous bases of the two separate dNTPs are bound together with 
hydrogen bonds to build double-stranded DNA.
A strict balance in dNTP pool sizes is critical for proper DNA replication 
and repair in eukaryotic cells (Reichard, 1988). When a cell proliferates, 
dNTP pool sizes fluctuate with the largest pools seen during S phase and the 
smallest in G1; which control the initiation of DNA replication (Chabes and 
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Stillman, 2007) (Figure 2). This fluctuation needs to be within a range 
optimal for chromosomal replication, as imbalances can impede DNA 
replication and repair resulting in DNA damage, cell cycle arrest or cell 
death (Mathews, 2006). Thus eukaryotes use diverse mechanisms to strictly 
regulate the supply of dNTPs (Pai and Kearsey, 2017). Ribonucleotide 
reductases (RNR) are the major contributors to the pool as they synthesize 
the dNTPs from ribonucleoside diphosphates (Figure 3) (Nordlund and 
Reichard, 2006). RNRs have long been recognized as an attractive target for 
cancer treatment, for their dysregulated activity is associated with genomic 
instability, malignant transformation and cancer development (Mathews, 
2015). 
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Figure 1. Structural elements of three nucleotides. Each in turn is attached 
to the nucleoside (in yellow, blue, green) at center: 1st, the nucleotide termed 
as a nucleoside monophosphate nucleotide is formed by adding a phosphate 
group (in red); 2nd, adding a second phosphate group forms a nucleoside 
diphosphate nucleotide; 3rd, adding a third phosphate group results in 
a nucleoside triphosphate nucleotide. + The nitrogenous base (nucleobase) is 
indicated by "Base" and "glycosidic bond" (sugar bond). All five primary, or 
canonical, bases—the purines and pyrimidines—are sketched at right (in 
blue).
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Figure 2. Schematic representation of dNTP levels throughout cell cycle 
progression. Highest dNTP levels are seen during S phase wheras lowest are 
during G1 phase. The Low G1-phase dNTP levels contribute to the G1 
checkpoint. (Franzolin et al., 2013)
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Figure 3. RNR and de novo dNTP biosynthesis. Mammalian RNR 
enzymes function to reduce the 2' carbon of NDPs to generate dNDPs that 
are subsequently phosphorylated by nucleoside diphosphate kinase, yielding 




1. SAMHD1 is a dNTPase
An additional mode of dNTP pool control was discovered in 2011 as two 
groups reported a novel enzyme SAMHD1, Sterile alpha motif (SAM) 
domain and Histidine-aspartic (HD) domain containing protein 1. It is 
expressed ubiquitously throughout human body, and mainly in the nucleus at 
cell level. It is the first deoxynucleotide triphosphohydrolase (dNTPase) 
discovered in mammalian cells, as it depletes the cellular dNTP levels by 
cleaving them to respective deoxyribonucleosides plus tripolyphosphate
(Figure 4) (Goldstone et al., 2011, Powell et al., 2011). This activity of 
SAMHD1 resides in its histidine-aspartate (HD) domain, while the N-
terminal sterile alpha motif (SAM) domain exhibit other activities including
substrate-binding. dGTP is reported to be its cofactor, as it binds to the 
allosteric sites of SAMHD1 and promotes tetramerization (Figure 5). Unlike 
inactive monomers or dimers, SAMHD1 tetramers show high enzymatic 
activities and facilitate various biological activities. In addition to the 
7
dNTPase activity, SAMHD1 is reported to have RNase and nuclease 
activities, although further validations are required.
8
Figure 4. Representative schematic of the important domains of 
SAMHD1. The enzymatic activity of SAMHD1 is promoted by the HD 
domain. SAMHD1 degrades dNTPs into deoxynucleosides (dN) and 
inorganic triphosphates (PPP). (Rossi, 2014)
9
Figure 5. Schematic illustration of the mechanism of SAMHD1 
activation by allosteric dGTP-induced tetramerization. Subunits of 
SAMHD1 are labeled A, B, C and D, and the catalytically inactive 
monomers and dimers are shown with empty substrate-binding pockets. 
Binding of four dGTP pairs at the allosteric sites promotes tetramerization 
and induces large conformational changes at the tetramer interface (AC and 
BD). This in turn causes conformational changes around the catalytic sites, 
enabling dNTP substrate binding in a catalytically productive conformation.
(Ji et al., 2013)
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2. SAMHD1 and innate immunity
Originally discovered as a component of the human innate immune system, 
SAMHD1 was first named as dendritic cell-derived IFN-γ induced protein 
(DCIP) as its levels were increased in response to IFN-γ treatment in 
dendritic cells (Li et al., 2000). Later studies revealed that mutations in 
SAMHD1 causes Aicardi-Goutières syndrome (AGS), a genetic 
encephalopathy whose symptoms mimic congenital infection (Rice et al., 
2009). However, the most widely-known function of SAMHD1 is its anti-
HIV-1 restriction activity. Observed in myeloid cells as well as in quiescent 
CD4+ T cells, SAMHD1 depletes the level of cellular dNTPs to the levels
insufficient for reverse transcription, therefore results in blockage of early-
stage retroviral replication (Figure 6) (Laguette et al., 2011, Hrecka et al., 
2011, Baldauf et al., 2012). Together, these findings suggest new ways to 




Figure 6. Effect of SAMHD1 on HIV-1 replication. After entry into the 
target host cell, viral RNA (vRNA) is converted into viral DNA (vDNA) by 
the viral reverse transcriptase, and the resulting provirus is integrated into the 
host nucleus. HIV-1 relies on cellular dNTPs for reverse transcription. 
Various cellular enzymes that target nucleic acids either positively or 
negatively affect the early steps of viral replication. SAMHD1, which is 
located in the nucleus, hydrolyses dNTPs in non-cycling cells, thereby 
limiting HIV-1 replication. In the presence of SAMHD1, HIV-1 reverse 
transcription is severely impaired and levels of replication are very low. 
(Ayinde et al., 2012)
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3. SAMHD1 and cell growth
Like RNR, which controls cell cycle progression by contributing to dNTP 
pools, SAMHD1 also plays role in cell cycle progression. SAMHD1 
stimulates cell proliferation in lung fibroblasts and THP-1 cells (Franzolin et 
al., 2013, Bonifati et al., 2016). SAMHD1 was variably expressed during the 
cell cycle, maximally during quiescence and minimally during S phase
(Figure 7). Low dNTP levels during G1 phase caused by high levels of 
SAMHD1 facilitated G1/S transition and resulted in increased cell 
proliferation in fibroblasts. 
Overall, as SAMHD1 controls the size of dNTP pool and cell cycle 
progression, there is a high possibility of its connection to cancer, similarly 
to RNRs. Indeed, SAMHD1 is reported to be frequently mutated in chronic 
lymphocytic leukemia and colon cancers (Clifford et al., 2014, Rentoft et al., 
2016). However, little has been investigated about its molecular mechanisms 
in cancer proliferation. 
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Figure 7. SAMHD1 expression change during cell proliferation.
Abundance of SAMHD1 (x), and two subunits of RNR, R2 (filled square), 
and p53R2 (filled triangle) at the indicated days of culture without siRNA. 
Left reports in aribitrary units the quantification of the immunoblots on the 
right. Notice the parallelism between R2 expression and frequency of S-
phase cells (open circle) in the cultures. (Franzolin et al., 2013)
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4. Posttranslational modifications of SAMHD1
Posttranslational modifications (PTMs) are the chemical modifications of a 
protein after its translation, which highly increases the functional diversity of 
the protein (Khoury et al., 2011). A variety of PTMs exist in mammalian 
systems, including phosphorylation, glycosylation and acetylation. In 2013, 
two groups independently reported the phosphorylation of SAMHD1. In 
cycling immune cells, CDK1 (cyclin-dependent kinase 1) and cyclin A2 
phosphorylates SAMHD1 at its T592 residue, which keeps SAMHD1 
inactive (Cribier et al., 2013, White et al., 2013). However, in non-cycling 
cells, SAMHD1 is dephosphorylated and shows anti-viral restriction activity
towards HIV-1 virus (Figure 8). However, this phosphorylation had no direct 
influence on the ability of SAMHD1 to decrease dNTP levels in vitro. These 
results raises the possibility that unknown forms of PTMs or non-cycling 
cell-specific cofactors may exist. Yet, other PTMs or molecular mechanisms 
that affects the dNTPase activity directly has not been discovered. 
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Figure 8. Model for the regulation of SAMHD1 restriction activity by 
phosphorylation at the Thr592 residue. SAMHD1 phosphorylation occurs 
at T592 residue by CDK1 and cyclin A2 in proliferative T-cells. 




Protein acetylation is one of the major PTMs in cell signaling and 
metabolism in eukaryotes as its regulation is crucial for various important 
cellular processes (Drazic et al., 2016, Choudhary et al., 2009, Zhao et al., 
2010). It is catalyzed by acetyltransferases, which transfer acetyl groups 
from the donor acetyl-CoA to the target proteins. Two types of acetylation
have been reported, Nα-terminal acetylation and Nε-lysine acetylation
(Figure 9). Nα-terminal acetylation is mediated by NATs (Nα-terminal 
acetyltransferases), as they acetylate the α-amino group of N-terminal 
residues of proteins. This is one of the most common protein modifications 
in eukaryotes, which occurs to about 80–90% of the cytosolic proteins in 
mammals and approximately 50% of proteins in yeast (Persson et al., 1985; 
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Lee et al., 1989). Nα-terminal acetylation is known to be co-translational and 
irreversible, contributing to protein stability and localization. NATs 
associated to the ribosome acetylates the N-terminal α-amino group of the 
nascent polypeptide newly synthesized and extruded from the ribosome. 
(Driessen et al., 1985).
Nε-lysine acetylation, on the other hand, is less common, but a very 
important form of protein acetylation which occurs post-translationally on 
the ε-amino group of lysines. When an acetyl group is added onto lysines, 
the positive charges on its amino group is neutralized, which results in a 
significant change in the electrostatic properties of the protein. This type of 
acetylation is crucial for regulating diverse functions of proteins, such as 
protein-protein interaction or protein stability (Glozak et al., 2005). Unlike 
the Nα-terminal acetylation, this form of acetylation is reversible; therefore 
the acetylation/ deacetylation of a specific residues are reported to act as 
important switches in the regulation of gene transcription, cellular growth 
and differentiation.
19
Many acetyltransferases can regulate their catalytic activity by 
acetylating themselves (auto-acetylation). For example, p300, an 
acetyltransferase, is highly auto-acetylated in its activation loop, which
results in its enhanced transcriptional activity (Karanam et al., 2006). 
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Figure 9. Comparison of two types of protein acetylation. N-terminal 
acetylation and lysine acetylation are compared. ARD1 shows both of the 
acetylation activities. (Jeong et al., 2002; Starheimm KK et al., 2012; Sharp 
FR et al., 2004)
21
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2. ARD1 is an acetyltransferase
Arrest defective 1 (ARD1) is an acetyltransferase. Interestingly, it is known 
to have both Nα-terminal acetylation and Lysine-acetylation activities (ref) 
(Figure 9). First discovered in Saccharomyces cerevisiae (Lee et al, 1989; 
Park and Szostak et al, 1990), ARD1 associates with NAT1 to form NAT 
complex, and acts as a catalytic component in yeast (Park and Szostak et al, 
1992).
Later studies have discovered various substrates of ARD1. Runt-related 
transcription factor 2 (Runx2) is known to transactivate many genes required 
for osteoblast differentiation. ARD1 acetylates this protein to block this 
transactivation, controlling balanced osteogenesis (Yoon et al., 2014). Heat 
shock protein 70 (HSP70) is also a recently-discovered substrate of ARD1. 
HSP70 acetylation acts as a functional switch to alter its activity from protein 
refolding to degradation (Figure 10) (Seo et al., 2016). Moreover, ARD1 is 
also auto-acetylated, which promotes the acetyltransferase activity of itself
(Seo et al., 2010). Altogether, these reports demonstrate that ARD1-mediated 
acetylation acts as an important switch of various substrates to alter their 
23
modes of action.
Figure 10. Schematics for functional switch of Hsp70 regulated by 
ARD1-mediated acetylation. After stress, ARD1 and Hsp70 are 
sequentially activated by an acetylation cascade. ARD1 selectively acetylates 
Hsp70 but not Hsc70. In the early phase after stress, Hsp70 is rapidly 
activated by acetylation to support protein refolding. In the late phase, 
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deacetylated Hsp70 contributes to protein degradation. (Seo et al., 2016)
3. ARD1 is oncogenic
When initially identified in yeast, ARD1 was reported as a mating-type 
switch that controls the mitotic cell cycle and alternative development 
(Whiteway and Szostak, 1985; Whiteway et al., 1987). Later, many studies 
have reported ARD1 to be oncogenic. It is highly expressed in several types 
of cancers including breast (Yu et al., 2009, Wang et al., 2011), prostate 
(Wang et al., 2012), lung and colorectal (Xu et al., 2012). Moreover, various
molecular mechanisms of ARD1 were discovered to promote tumorigenesis. 
For example, ARD1 is proposed to promote the lung cancer cell proliferation 
by acetylating b-catenin (Lim et al., 2006; Lim et al, 2008). In prostate 
cancer, ARD1 activates androgen receptor (AR) by acetylation to promote 
prostate tumorigenesis (Wang et al., 2012). 
Recent study has demonstrated that the nuclear translocation of ARD1 is 
required for cell cycle progression (Figure 11) (Park et al., 2014). In 
proliferating cells, ARD1 is imported to the nuclei especially during S phase, 
contributing to proper cell proliferation in HeLa and A549 cancer cell lines. 
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Altogether, these growing evidence suggest that ARD1 contributes to cancer 
proliferation.
Figure 11. Schematic diagram showing the contribution of ARD1 in 
cell cycle progression. (Park et al., 2014)
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PURPOSE OF THIS STUDY
SAMHD1 is the first dNTPase discovered in human cells which contributes 
to anti-retroviral defense by lowering the cellular dNTP pool levels in non-
cycling myeloid cells. This restrictive activity is not shown in cycling cells, 
implying the existence of posttranslational modifications or cofactors 
specifically expressed in non-cycling cells. However, molecular mechanisms 
that directly regulates its enzymatic activity has not been reported, as its 
phosphorylation did not alter its dNTPase activity in vitro. Moreover, 
previous studies were mainly limited to its functions in immune cells, despite 
its ubiquitous expression throughout the body. SAMHD1 was reported to 
facilitate G1-to-S phase progression in monocytes and fibroblasts, yet further 
studies on functions of SAMHD1 in other cell types are required.
In this study, I present SAMHD1 as a novel acetylation substrate of ARD1.
As protein acetylation can modulate the activities of the substrate proteins, I 
hypothesized that ARD1 may acetylate SAMHD1 to alter its dNTPase
activity. Moreover, as ARD1 is reported to be oncogenic and the enzymatic 
activity of SAMHD1 is relevant to the cell cycle regulation, I investigated 
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whether the ARD1-mediated SAMHD1 acetylation contribute to cancer cell 
proliferation. By identifying the specific acetylation site of SAMHD1 and 
mutating it to block its acetylation, I aimed to discover a novel function of 
SAMHD1 acetylation in cancer cell growth. 
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MATERIALS AND METHODS
1. Human liver tissue samples
Hepatocarcinoma tissues and surrounding non-tumorous liver samples were 
obtained from patients at Asan Hospital (Seoul, Republic of Korea). 
Clinicopathological characteristics of hepatocarcinoma patients are 
summarized in Table S1. This study was approved by Institutional Review 
Board of Asan Hospital, and written informed consent was obtained from all 
the patients.
2. Cell culture and synchronization
HeLa, A549, Hep3B, MCF-7 and HEK293T cells were grown in DMEM 
supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin in 5% CO2 humidified atmosphere at 37°C. For 
serum starvation, cells were incubated in DMEM without serum for 48 h and 
re-stimulated with DMEM containing 10% FBS. A double thymidine block 
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was performed to synchronize cell populations in S phase. Cells were treated 
with 2 mM thymidine (Sigma-Aldrich) for 18 h, cultured for 9 h in normal 
growth medium, and then retreated with thymidine for another 16 h. After 
removing the thymidine, cells were released to normal medium and 
harvested at the indicated times.
3. in vitro acetylation assay
Acetylation assay was performed as described previously [19]. Briefly, 1 μg 
of purified recombinants or precipitated cellular proteins were incubated in 
the reaction mixture containing 50 mM Tris–HCl (pH 8), 0.1 mM EDTA, 
1 mM DTT, 10% glycerol and 10 mM acetyl-CoA at 37 °C for 1.5 h. 
Reaction products were separated by SDS–PAGE and were analyzed by 
western blot using anti-Lys-Ac antibody. Input proteins were visually 
quantified using Coomassie brilliant blue staining or Ponceau S staining.
4. Mass spectrometric analysis
Mass spectrometric analysis was performed as previously described [30]. For 
enzymatic digestion of recombinant SAMHD1, two GST-SAMHD1 samples 
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used in the in vitro acetylation assay (incubated with ±ARD1) were 
immediately denatured using 6 M GuHCl and were reduced with 5 mM DTT 
for 30 min at room temperature, then alkylated with 25 mM iodoacetamide 
for 30 min. Glu-C digestions were carried out for 6 h at 25 °C then were 
quenched by 5% formic acid. Micro RPLC–MS/MS analysis was performed 
as previously described [22].
5. in vitro dNTPase assay
An enzymatic assay based on thin-layer chromatography was performed as 
described previously [9]. The purified recombinant or immunoprecipated 
cellular protein (1 μg) was incubated in reaction mixture composed of 50 
mM Tris-Cl (pH 8.0), 20 mM KCl, 5 mM MgCl2, 0.1 μCi [α-32P]dTTP, and 
200 μM ice-cold dGTP for 3 h at 37 °C. The reactions were stopped by heat 
inactivation at 70 °C for 10 min. Mixtures were blotted onto 
polyethyleneimine (PEI)-cellulose plates (Sigma-Aldrich) and subsequently 
separated using a mobile phase of 1.2 M LiCl. After separation, the α-32P-
labeled reaction products were visualized using a phosphorimager.
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6. siRNA and plasmid construction
The siRNA sequence targeting human SAMHD1 corresponds to 
GAUUCAUUGUGGCCAUAUA as previously described [9]. Full-length of 
cDNAs for human SAMHD1 (Genbank: NM_015474) and human ARD1 
(Genbank: NM_003491.3) were obtained from PCR and subcloned into 
pCDNA3.1 (FLAG-SAMHD1), pCMV-tag2b (FLAG-ARD1), pEGFP-C3 
(GFP-ARD1) and pCS2+ (MYC-ARD1) vectors for cellular expression or 
pGEX-4T (GST-SAMHD1) and pET28a (His-ARD1) vectors for the 
bacterial induction of recombinant proteins. Deletion mutants of GST-
SAMHD1 were constructed from pGEX-4T-SAMHD1 plasmid. cDNAs of 
SAMHD1 corresponding to 34–113 aa, 160–339 aa and 334–626 aa were 
amplified by PCR and inserted into pGEX-4T-1. For construction of stable 
cell lines, cDNAs of SAMHD1 was co-inserted into pMX-IRES-
BlasticidinR vector with PCR-amplified FLAG. Point mutations in 
SAMHD1 (K405R and K580R) and ARD1 (K136R and DN: R82A/Y122F) 
were generated using the Muta-Direct Site Directed Mutagenesis kit (Intron) 
according to the manufacturer’s instructions. The following primers and its 








7. Transfection and Stable Cell Line Construction
Transfection was performed as described previously [22]. I transfected 
HEK293T cell with polyethyleneimine (PEI) at a ratio of 3:1 (μl PEI/μg
plasmid DAN) in basal media overnight. siRNA targeting SAMHD1 was 
transfected with HiPerFect reagent (Quiagen) according to the manufacture’s 
instruction.
For the establishment of stable cells, pIRES-FLAG-SAMHD1 plasmids were 
transfected into Platinum A cells and retroviral supernatants were harvested 
72 h after transfection. Collected supernatants were used to transduce target 
cell lines (HeLa, A549, Hep3B and MCF-7) with polybrene (10 μg ml−1). 
Transduced cells were selected using blasticidin (10 μg ml−1). Expression of 
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FLAG-SAMHD1 was quantified by western blot.
8. Immunoblotting and immunoprecipitation
Cellular proteins were extracted using cell lysis buffer composed of 20 mM 
Tris-CL (pH 7.5), 150 mM NaCl, 0.1 mM EDTA, 0.1% Triton X-100 and a 
protease inhibitor cocktail (Roche). 20 ~50 μg of cell extracts were used for 
immunoblotting. For immunoprecipitation, 1 mg of proteins were incubated 
with corresponding primary antibody conjugated to A or G bead (Upstate) or 
Anti-DDDDK-tag mAb-Magnetic Agarose (MBL) overnight at 4 °C. Beads 
were washed three times with washing buffer containing 20 mM Tris-Cl (pH 
7.5), 150 mM NaCl and 0.1 mM EDTA. After SDS–PAGE, membranes were 
immunoblotted using the corresponding primary antibody overnight at 4 °C. 
HRP-conjugated secondary antibodies were incubated with the membranes 
for 1 h at room temperature. Visualization was performed using ECL Plus 
(Intron) and LAS-4000 (GE Healthcare). 
9. Screening of binding proteins
The protein-protein interaction assay was performed as reported previously 
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[22]. HEK293T cells were transiently transfected with FLAG-HA tagged 
ARD1 and were lysed in lysis buffer consisting 20 mM Tris-Cl (pH 7.5), 
150 mM NaCl, 0.1 mM EDTA, 0.2% Triton X-100 and a protease inhibitor 
cocktail (Roche). Cell lysates were incubated with anti-M2 resin (Sigma) for 
2 h at 4 °C, then resins were collected by centrifugation and washed three 
times with washing buffer, composed of 20 mM Tris-Cl (pH 7.5), 150 mM 
NaCl and 0.1 mM EDTA. Bound proteins were eluted by 3 × FLAG-peptide 
and were immunoprecipitated again using anti-HA-antibody for 2 h at 4 °C. 
The bound proteins were analyzed by SDS–PAGE and silver staining.
10. Recombinant protein preparation 
BL21 cells were transformed with plasmids pGEX-4T-1-SAMHD1 or 
pET28a-ARD1 and were grown to and OD600 of 0.6–0.8. 1 mM IPTG was 
added to induce GST-tagged SAMHD1 or His-tagged ARD1, then cells were 
grown overnight at 20 ℃. Cells were collected and proteins were extracted 
with a lysis buffer consisting 50 mM Tris–HCl (pH 8), 250 mM NaCl, 
2.5 mM EDTA and 1% Triton X-100. GST-tagged and His-tagged proteins 
were purified with Glutathione Sepharose 4B (GE Healthcare) and TALON® 
Metal Affinity Resins (Clontech), respectively. Resin-bound proteins were 
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eluted with an elution buffer containing 50 mM Tris–HCl (pH 8) and 10 mM 
reduced glutathione (GSH). 
11. Protein sequence alignment 
SAMHD1 multiple protein sequence alignment was conducted by 
Constraint-based Multiple Alignment Tool provided from NCBI. 
12. Flow cytometry analysis
For a flow cytometry assay, cells were collected, fixed in 1% PFA, and 
stored at 4°C for 30 min. Cells were then washed with PBS and stained with 
propidium iodide (PI, 30 μg ml−1) mixed with RNase A (1 μg ml−1) for 15 
min at 37℃. The DNA content of cells was assessed with a FACS-Verse 
system (BD Biosciences), and cell cycle profiles were analyzed with the BD 
FACSuite software. At least 30,000 cells in each sample were analyzed to 
obtain a measurable signal, using the same instrument setting.
13. Cell proliferation assay
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The proliferation rates were measured using a Cell Proliferation Assay kit 
(Promega) following the manufacturer's instructions. Briefly, 2×103 
cells/well were seeded onto 96-well plates and were allowed to grow. At 
indicated time points, 20 µL of substrate solution was added to the cells and 
were incubated for 1 h for color development. The absorbance at 492 nm was 
measured to indicate the number of proliferating cells.
14. Colony formation assay
Colony formation assays were performed as described previously [31]. For 
anchorage dependent colony formation, cells were seeded at a density of 100 
cells/well onto 6-well plates and were allowed to grow for 2 weeks. Cells 
were then fixed with 100% methanol, stained with 0.005% crystal violet and 
the number of colonies were counted. For anchorage independent colony 
formation, cells were resuspended in 0.5 mL DMEM containing 0.4% agar 
and were seeded onto a layer of 1% agar in 12-well plates. After 2 weeks of 
incubation, colonies were stained with 0.005% crystal violet and counted.
15. Fluorescence microscopy
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For the analysis of PCNA by flourescence microscopy, cells were seeded 
onto the glass coverslips in 24-well plates. After synchronization, cells were 
fixed in 2% PFA for 20 min and were permeabilized in 1% triton X-100 in 
PBS 10 min at room temperature. Then, cells were incubated with PCNA 
antibody (Cell signaling) and visualized with Alexa 488-conjugated igG 
(Molecular Probes). Nucleus staining was performed with Hoechst 33342 
(Molecular Probes). The immunofluorescence was visualized using a 
confocal microscopy (Carl Zeiss, LSM700).
16. Statistical analysis
Results are expressed as the mean’s±s.d’s or±s.e.m’s. P values were 
calculated by applying the two-tailed Student’s t test or one-way ANOVA. A 
difference was considered statistically significant at a value of P<0.05.
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RESULTS
1. SAMHD1 is a novel acetylation substrate of ARD1
As ARD1 is an acetyltransferase, I first aimed to find its novel substrates to 
study the functions of ARD1. For this I have screened for ARD1-binding 
proteins using affinity purification combined with mass spectrometry. 
FLAG/HA-tagged ARD1 proteins were overexpressed in HEK293T cells, 
then immunoprecipitated overnight. The resin-bound proteins were separated 
by SDS-PAGE and the gel was silver stained for protein identification. 
Around 72 kDa, two strong bands were observed; one of them was identified
to be HSP70 protein as previously reported (Seo et al., 2016). The other 
anonymous band was subjected to mass spectrometry for identification, 
which was revealed to be endogenous SAMHD1 protein (Figure 12). To 
confirm this result, FLAG mock or ARD1 expressing vectors were 
transfected to HEK293T cells and the lysates were immunoprecipitated using 
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FLAG-specific resin. When precipitates were separated by SDS-PAGE and 
immunoblotted by SAMHD1 specific antibody, the endogenous SAMHD1 
proteins were found to be co-immunoprecipitated, in accordance to the 
previous result (Figure 13). These data demonstrates that SAMHD1 is a 
novel binding partner of ARD1.
Next, as ARD1 is an acetyltransferase, I investigated whether it could 
acetylate SAMHD1. Recombinant GST-SAMHD1 proteins were induced 
and purified from E. coli, then subjected to an in vitro acetylation assay with 
or without His-ARD1 in the presence of Acetyl-CoA. The protein was found 
to be acetylated when His-ARD1 was present, demonstrating that ARD1 
directly acetylates SAMHD1 in vitro (Figure 14). To test this acetylation in 
vivo, GFP-mock or ARD1 vectors were overexpressed in HEK293T cells. 
The lysed proteins were incubated with Lys-Acetylation specific antibody to 
selectively immunoprecipitate Lys-Acetylated proteins. When the products 
were separated and blotted with SAMHD1 antibody, the intensity of 
endogenous SAMHD1 acetylated forms was observed to be stronger in GFP-
ARD1 overexpressing cells than the mock cells, confirming the in vitro data
(Figure 15). Together, these data indicate that SAMHD1 is acetylated by 
ARD1.
40
Our lab has previously reported that ARD1 is autoacetylated at K136 
residue to enhance its catalytic activity (Seo et al., 2010). To test whether this 
affects SAMHD1 acetylation, I overexpressed K136R mutant FLAG- ARD1, 
which cannot be autoacetylated therefore shows less acetyltransferase 
activity. In addition, dominant negative (DN) mutants of ARD1 which does 
not exhibit any enzymatic activity at all were also expressed in HEK293T 
cells. When the Lys-acetylation intensity of endogenous SAMHD1 from 
these cells were evaluated, they were significantly decreased compared to the 
ARD1 wildtype expressing cells (Figure 16). This result indicates that the 
two ARD1 mutants blocked SAMHD1 acetylation; therefore it is suggested 
that ARD1-autoacetylation is required for SAMHD1 acetylation as an up-
stream signal.
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Figure 12. LC-MS/MS analysis reveals SAMHD1 as a novel binding 
partner of ARD1. HEK293T cells were transfected with FLAG/HA-ARD1 
and lysed proteins were immunoprecipitated, separated by SDS-PAGE and 
silver stained. * refers to SAMHD1.
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Figure 13. Co-immunoprecipitation of endogenous SAMHD1 and
FLAG-ARD1. FLAG-ARD1 was immunoprecipitated from HEK293T cells, 
and co-precipitation of endogenous SAMHD1 was analyzed by western blot.
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Figure 14. Recombinant SAMHD1 protein is acetylated by ARD1 in vitro.
Recombinant GST-SAMHD1 proteins were subjected to in vitro acetylation 
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assay with ±His-ARD1. The acetylation level was determined with anti-Lys-
Ac antibody.
Figure 15. Endogenous SAMHD1 protein is acetylated by ARD1 in vivo.
Lys-acetylated proteins were precipitated from GFP-mock or ARD1 
expressing HEK293T cells and were blotted with anti-SAMHD1 antibody.
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Figure 16. Endogenous SAMHD1 protein is less acetylated by ARD1
mutants in vivo. FLAG-ARD1 wildtype, K136R and DN mutants were 
overexpressed in HEK293T. Lysed proteins were precipitated with anti-Lys-
Ac antibody and were blotted with anti-SAMHD1 antibody.
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2. K405 residue of SAMHD1 is acetylated by ARD1.
Next, to identify the target site of acetylation, I constructed three types of 
deletion mutants of SAMHD1 according to their functional motifs; SAM 
domain (SAM), HD domain (HD) and C-terminal domain (CTD) (Figure 17).
These vectors were transformed in to E.coli for induction and purification of 
corresponding recombinant proteins. When these proteins were subjected to 
in vitro acetylation assay in the presence of His-ARD1, only CTD was found 
to be acetylated, indicating that CTD is the major acetylated domain (Figure 
18). To find the specific amino acid residue of acetylation, acetylated and 
non-acetylated GST-CTD were prepared by incubating with or without His-
ARD1. Then, these products were digested into peptides and subjected to 
micro-liquid chromatography-tandem mass spectrometry (LC–MS/MS).
When the acetylated sites were compared between the two, 2 potential 
acetylation sites were discovered; K405 and K580 (Figure 19). To verify the 
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critical site between the two and to establish the causality of this relationship,
I mutated K405 and K580 of recombinant SAMHD1 to Arg 405 (K405R) 
and Arg 580 (K580R) residue respectively, to block their acetylation. When 
these mutants were subjected to in vitro acetylation, only K405R mutant 
showed decreased acetylation level, indicating that K405 is the main target 
site for acetylation and K580 as the minor site (Figure 20). To confirm this in 
vivo, FLAG-SAMHD1 K405R and K580R were constructed and 
overexpressed in HEK293T cells. When their acetylation levels were 
assessed by Lys-Ac antibody, K405R SAMHD1 showed a decreased 
acetylation level compared to wildtype or K580R expressing cells (Figure 
21). Overall, these result demonstrates that ARD1-mediated SAMHD1 
acetylation occurs at the K405 residue. 
Proteins with key biological functions commonly have homologues from 
many different tissues and organisms. Therefore multiple sequence 
alignment of the protein from various species can highlight the conserved 
residues critical for its common function and key structure (Livingstone and 
Barton, 1993). Therefore to estimate the importance of K405 residue-specific 
acetylation, I investigated whether K405 residue is conserved among various 
species. Alignment of SAMHD1 amino acid sequence from various species 
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were carried out using BLAST (Basic Local Alignment Search Tool), which 
revealed that K405 residue is highly conserved especially in mammals, from 
human to Mus Musculus. Also, K405 was conserved in amphibians such as 
Xenopus, but not in fish such as Danio Rerio. Together, these result indicate
that this acetylation site may be critical for its biological functions or protein 
structure in many species (Figure 22). To identify the structural importance 
of K405 acetylation, structural analysis was carried out using PyMOL 
software. The location of K405 was distant from the catalytically critical 
sites such as allosteric sites or substrate binding regions, but further studies 
are required to investigate its structural importance (Figure 23). In summary, 
ARD1-mediated SAMHD1 acetylation occurs at K405 residue, which is 
highly conserved among various species.
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Figure 17. Construction of SAMHD1 deletion mutants. SAMHD1 
deletion mutants were constructed according to their functional motifs. SAM; 
SAM domain, HD; HD domain, CTD; C-terminal domain.
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Figure 18. Recombinant CTD protein of SAMHD1 was mainly 
acetylated by ARD1 in vitro. Deletion mutants of GST-SAMHD1 were 
subjected to in vitro acetylation assays with ±His-ARD1 and blotted with 






Figure 19. Acetylated sites of GST-SAMHD1 CTD. Recombinant GST-
CTD were acetylated in vitro in the presence of recombinant ARD1 protein 
and subjected to LC–MS/MS to identify the acetylated sites. (A) K405 and 
relative ion abundance (B) K580 and relative ion abundance
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Figure 20. K405 is the major site of ARD1-mediated acetylation of 
SAMHD1 in vitro. GST-SAMHD1 recombinants were subjected to in vitro
acetylation assays with His-ARD1. Acetylation levels were determined with 
an anti-Lys-Ac antibody.
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Figure 21. K405 is the major site of ARD1-mediated acetylation of 
SAMHD1 in vivo. FLAG-SAMHD1 variants were immnunoprecipitated
from HEK293T cells, and their acetylation levels in vivo were analyzed 
using an anti-Lys-Ac antibody.
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Figure 22. Sequence alignment of SAMHD1 K405 residue in various 
species.
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Figure 23. Location of K405 residue in SAMHD1 structure. Blue, orange, 
yellow and green colors represent each SAMHD1 monomers. Red indicates 
Lys 405 residue.
3. ARD1-mediated SAMHD1 acetylation enhances its dNTPase activity
As SAMHD1 is a dNTPase, I investigated whether SAMHD1 acetylation 
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could regulate this activity directly. By using in vitro dNTPase assay, I tested 
the ability of recombinant acetylated and non-acetylated SAMHD1 to 
hydrolyze α-32P labeled thymidine triphosphate (α-[32P]TTP) to 
deoxythymidine (dT) and α-[32P]PP (Figure 24). In this assay, the released 
amount of α-[32P]PP is considered as the marker for dNTPase activity; the 
more α-[32P]PP  is released, the stronger the enzymatic activity is. First, the 
GST-SAMHD1 proteins were subjected to in vitro acetylation assay with or 
without His-ARD1 to produce acetylated and non-acetylated SAMHD1 
proteins, respectively. Then the products were incubated with α-[32P]TTP and
separated using thin layer chromatography to compare the amount of 
released α-[32P]PP. The acetylated SAMHD1 released more α-[32P]PP, 
indicating its higher enzymatic activity over the non-acetylated protein 
(Figure 25). To confirm this result, the K405R mutant SAMHD1 were also 
subjected to acetylation and dNTPase assay. As a result, the increase of 
activity found in wild type SAMHD1 was diminished in K405R mutant, as it 
could not be acetylated (Figure 26). Together, these results demonstrates that 
ARD1-mediated SAMHD1 acetylation directly enhances its dNTPase 
activity in vitro. 
To confirm the phenomena in vivo, FLAG-SAMHD1 wildtype and K405R 
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mutant proteins were overexpressed and purified from HEK293T cells. 
When these proteins were subjected to dNTPase activity, SAMHD1 wildtype 
showed enhanced enzymatic activity over the K405R mutant, similarly to in 
vitro results (Figure 27). To test whether this was affected by ARD1, MYC-
ARD1 were co-expressed with FLAG-SAMHD1 wildtype or K405R in 
HEK293T cells. When these SAMHD1 proteins were purified from these 
cells and their dNTPase activities were assessed, the amount of released α-
[32P]PP were increased in FLAG-SAMHD1 wildtype and MYC-ARD1 co-
expressing cells compared to MYC-mock expressing cells (Figure 28).
However, SAMHD1 K405R mutant proteins showed no difference whether 
co-expressed with ARD1 or not. Overall, these data suggest that the ARD1-
mediated SAMHD1 acetylation enhances its dNTPase activity in vitro and in 
vivo. 
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Figure 24. Schematic representation of in vitro dNTPase assay. 
Figure 25. SAMHD1 acetylation upregulates its dNTPase activity in vitro.
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Recombinant GST proteins and GST-SAMHD1 proteins were acetylated in 
vitro with ±His-ARD1 and blotted with anti-Lys-Ac antibody (lower right). 
Products were subjected to in vitro dNTPase assay and imaged using a 
phosphorimager (Left). The released amount of α-[32P]PP were measured 
and presented as mean ±S.D. (n=3) (upper right). **P<0.01; t-test
Figure 26. SAMHD1 K405R mutant does not show upregulated
dNTPase activity in the presence of ARD1 in vitro. Recombinant GST-
SAMHD1 WT and K405R proteins were acetylated in vitro with ±His-ARD1 
and blotted with anti-Lys-Ac antibody (lower right). Products were subjected 
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to in vitro dNTPase assay and imaged using a phosphorimager (Left). The 
released amount of α-[32P]PP were measured and presented as mean ±S.D. 
(n=3) (upper right). **P<0.01; t-test
Figure 27. SAMHD1 WT shows stronger dNTPase activity over K405R 
mutant in vivo. FLAG-mock, SAMHD1 wildtype or K405R mutants were 
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overexpressed and immunoprecipitated from HEK293T (lower right). 
Precipitated proteins were subjected to in vitro dNTPase assay (left) and 
were quantified (upper right). Shown are mean ±S.D. (n=3). **P<0.01; t- test
Figure 28. SAMHD1 WT shows stronger dNTPase activity in the 
presence of ARD1 in vivo. FLAG- SAMHD1 WT or K405R mutants were 
overexpressed with ±MYC-ARD1, then FLAG-tagged proteins were 
immunoprecipitated from HEK293T (lower right). Precipitated proteins were 
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subjected to hydrolysis (left) and were quantified (upper right). Shown are 
mean ±S.D. (n=3). *P<0.05; **P<0.01; t- test, N.S.; not significant
4. SAMHD1 acetylation is important for cell proliferation in various 
cancer cells 
In proliferating cell populations, the supply of dNTPs needs to be strictly 
balanced for proper DNA replication and repair. Indeed, SAMHD1 is 
reported to control intracellular pool of dNTP via its dNTPase activity and 
promotes cell cycle progression in monocytes and fibroblasts. Since ARD1 is 
oncogenic and ARD1-mediated SAMHD1 acetylation enhances its 
enzymatic activity, I hypothesized that SAMHD1 acetylation may also 
regulate cell proliferation in cancer. However, little has been investigated
about the relationship between SAMHD1 expression and tumorigenesis; thus 
I first aimed to establish the connection between the two. To investigate the 
SAMHD1 expression level changes between tumor and normal tissues, the 
hepatocarcinoma tissues (tumor tissues) and surrounding normal tissues
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(non-tumor tissues) were collected from 7 patients; their clinicopathological 
characteristics are listed in table 1. Then SAMHD1 expression levels were 
analyzed by western blot, which revealed an increase of SAMHD1 levels in 
the tumor tissues than non-tumor tissues; statistical analysis confirmed the 
significance of this increase (Figure 29). This result suggests that SAMHD1 
may be related to hepatocellular tumorigenesis. Moreover, the level of ARD1 
was also elevated in tumor tissues as previously reported (Shim et al., 2012), 
implying the possibility that ARD1-mediated SAMHD1 acetylation level 
may have been upregulated in hepatocarcinoma, and that combined action of 
the two enzymes may be positively linked to cell proliferation in tumor cells
Next, to investigate whether SAMHD1 shows tumorigenic activity in 
cancer cell lines in vitro, SAMHD1 was silenced in various cancer cell lines
by transfecting SAMHD1-specific siRNA (Figure 30). When siCtrl and 
siSAMHD1 transfected HeLa cells were subjected to MTS assay to assess 
their growth rate, SAMHD1-downregulated HeLa showed relatively slow 
growth compared to the control cells (Figure 31). In accordance, control and 
SAMHD1-silenced MCF7 cells were subjected to anchorage-dependent 
colony formation assays, which resulted in decreased number of colonies 
formed in SAMHD1-silenced cells (Figure 32). These results indicate that 
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SAMHD1 expression promotes cancer cell growth. 
I next investigated whether SAMHD1 acetylation can affect this 
phenomena. First, stable cell lines expressing SAMHD1 wildtype and 
K405R mutant were constructed in HeLa, MCF7, A549 and Hep3B cells, 
which are derived from cervical cancer, breast adenocarcinoma, lung cancer 
and hepatocarcinoma, respectively (Figure 33). When the growth rate of 
stable HeLa cells were analyzed by MTS assay, overexpression of SAMHD1 
wildtype resulted in increased growth rate over the mock cells, whereas 
K405R mutant could not (Figure 34). Moreover, wildtype expressing MCF7 
cells exhibited increased number of colonies over mock or K405R 
expressing cells when subjected to anchorage dependent colony formation 
assay (Figure 35). This result was also confirmed in A549 and Hep3B cells, 
as they too showed increased colony forming abilities only in the wildtype 
expressing cells (Figure 36, Figure 37).
Anchorage-independent colony formation assay, or the soft-agar assay is a 
common method to measure the ability of transformed cells to grow 
independently of a solid surface; a hallmark of carcinogenesis. (Borowicz et 
al., 2014) To investigate the role of SAMHD1 acetylation in malignant 
transformation, stable HeLa cells were subjected to soft agar assay. 
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SAMHD1 wildtype expressing cells showed increased growth over mock or 
K405R expressing cells, indicating that SAMHD1 acetylation may 
contribute to the malignancy of the cancer cells (Figure 38). Taken altogether, 
these data demonstrate that SAMHD1 acetylation increases its ability to 
promote cancer cell proliferation. 















































Abbreviations: M, male; F, female; HBV, hepatitis B virus; NBNC, non-B 
non-C; HCV, hepatitis C virus
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Figure 29. Expression of SAMHD1 in hepatocarcinoma tissues and 
surrounding normal tissues. Tumor and non-tumor tissues from 7 
hepatocarcinoma patients were lysed and extracted. Protein expression levels 
were analyzed by western blot and presented as mean ±S.E.M. (n=7). T, 
Tumor tissues; N, Non-tumor surrounding tissues;*P<0.05; t- test
Figure 30. Establishment of SAMHD1-downregulated cancer cells. HeLa 
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and MCF7 cells were transfected with siCtrl or siSAMHD1 and were lysed 
after 48~72h. The level of proteins were assessed by western blot.
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Figure 31. Relative cell growth of SAMHD1-downregulated HeLa cells. 
Cell growth of siCtrl or siSAMHD1 treated HeLa cells were monitored over 
time by MTS assay. Shown are mean ±S.E.M. (n=5). *P<0.05; 
****P<0.0001; t test; N.S.; not significant 
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Figure 32. SAMHD1-downregulated MCF7 cells show decreased 
anchorage-dependent colony formation. siCtrl or siSAMHD1 treated 
MCF7 cells were subjected to anchorage-dependent colony formation assays. 
Number of colonies were presented as mean ±S.D. (n=3) with representative 
well pictures. **P<0.01; t test
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Figure 33. Establishment of FLAG-SAMHD1 WT or K405R 
overexpressing stable cancer cell lines. SAMHD1 wildtype or K405R 
expressing stable cell lines were constructed in HeLa, A549, Hep3B, and 
MCF7 cells and their protein levels were assessed by western blot.
74
Figure 34. Relative cell growth of FLAG-SAMHD1 WT or K405R 
overexpressing HeLa cells. Cell growth of stable HeLa cells expressing 
SAMHD1 wildtype, K405R or empty vector were monitored over time by 
MTS assay. Shown are mean ±S.E.M. (n=5). *P<0.05; ***P<0.001; 
****P<0.0001; t- test; N.S.; not significant 
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Figure 35. Anchorage-dependent colony formation of FLAG-SAMHD1 
expressing stable MCF7 cells. Stable MCF7 cells expressing SAMHD1 
wildtype, K405R or empty vector were subjected to anchorage-dependent 
colony formation assays. Number of colonies were presented as mean ±S.D. 
(n=3) with representative well pictures. *P<0.05; t- test
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Figure 36. Anchorage-dependent colony formation of FLAG-SAMHD1 
expressing stable A549 cells. Stable A549 cells expressing SAMHD1 
wildtype, K405R or empty vector were subjected to anchorage-dependent 
colony formation assays. Number of colonies were presented as mean ±S.D. 
(n=3) with representative well pictures. *P<0.05; t- test
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Figure 37. Anchorage-dependent colony formation of FLAG-SAMHD1 
expressing stable Hep3B cells. Stable Hep3B cells expressing SAMHD1 
wildtype, K405R or empty vector were subjected to anchorage-dependent 
colony formation assays. Number of colonies were presented as mean ±S.D. 
(n=3) with representative well pictures. *P<0.05; t- test
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Figure 38. Anchorage-independent colony formation of FLAG-
SAMHD1 expressing stable HeLa cells. Stable HeLa cells expressing 
SAMHD1 wildtype, K405R or empty vector were subjected to anchorage-
independent colony formation assays. Number of colonies were presented as 
mean ±S.D. (n=3) with representative well pictures. **P<0.01; t- test
5. SAMHD1 acetylation promotes G1/S transition in cancer cells
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SAMHD1 has been previously reported to control cell cycle status in 
mammalian cells by regulating DNA precursor pools (Franzolin et al., 2013, 
Bonifati et al., 2016). To determine whether cell cycle progression is altered 
by SAMHD1 in cancer cells, SAMHD1-silenced HeLa cells were 
synchronized by 48h of serum-starvation and re-stimulated for 24 h, then
subjected to flow cytometry for cell cycle analysis. Depletion of SAMHD1 
caused G1 arrest, as G1/G0 population increased whereas S and G2/M 
populations relatively decreased (Figure 39). Western blot analysis also 
revealed that the expression levels of cyclin D1 and B1, markers for S and 
G2/M phase respectively, were decreased in siSAMHD1 treated cells (Figure 
40). Therefore, these data indicate that SAMHD1 contributes to G1/S 
transition in HeLa cells.
Next, to identify the role of SAMHD1 acetylation in G1/S transition, stable 
A549 cells expressing FLAG-mock, SAMHD1 wildtype or K405R were also 
serum-starved and re-stimulated for cell cycle analysis. Unlike the K405R 
mutant, SAMHD1 wildtype expressing cells exhibited increased G1-to-S 
phase progression (Figure 41). This result was also confirmed by the 
expression levels of cyclin D1 and B1 (Figure 42). The immunofluorescence 
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images of proliferating cell nuclear antigen (PCNA), which is mainly 
expressed during the S phase, also reflected the increased S phase in 
SAMHD1 wildtype expressing Hep3B cells, but not in K405R cells (Figure 
43). Collectively, these data demonstrates that SAMHD1 acetylation 
contributes to G1/S transition in various cancer cell lines.
To validate the role of SAMHD1 acetylation in cell cycle progression in 
detail, I next checked the acetylation level during each phases. Using either 
thymidine-double block method or serum-starvation method, cancer cells
stably expressing FLAG-SAMHD1 wildtype were synchronized to the 
specific cell phases. Then FLAG-tagged proteins were immunoprecipited
and blotted with Lys-Ac antibody to analyze their levels of Lys-Acetylation.
In A549 cells, the intensity of acetylated SAMHD1 was the strongest in the 
G1/G0 phase and weakest in S phase, indicating that SAMHD1 was mainly 
acetylated during G1 phase (Figure 44). This phenomena was also observed 
in HeLa cells (Figure 45). These data suggest the possibility that the 
dNTPase activity of SAMHD1 may be strongest during the G1/G0 phase. 
Previous report has demonstrated SAMHD1 expression level fluctuate
throughout the cell cycle, which contributed to dNTP level changes and thus 
facilitated proper cell cycle progression in fibroblasts (Franzolin et al., 2013). 
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To investigate whether this phenomena is also seen in cancer cells, various 
cancer cells were synchronized to specific cell cycle phases and their 
endogenous SAMHD1 expression levels were assessed by western blot 
analysis. However, their levels displayed no significant difference in Hela,
Hep3B, A549 and MCF7 cells (Figure 46, Figure 47, Figure 48 and Figure 
49). Collectively, these results indicate that the difference in cell cycle 
progression between SAMHD1 wildtype and mutant expressing cells is 
caused by its acetylation, not by its expression level change. Taken altogether, 
SAMHD1 acetylation mainly occurs during G1 phase and promotes tumor 
growth via facilitating G1/S cell cycle progression.
CDK1 and cyclin A2 binds and phosphorylates SAMHD1 and to block its 
anti-retroviral activity. To test whether SAMHD1 acetylation influences 
SAMHD1 phosphorylation, I investigated whetherSAMHD1 acetylation can 
alter the binding of SAMHD1 and cyclin A2. FLAG-SAMHD1 wildtype and 
K405R expressing HEK293T cells were lysed and the lysates were 
immunoprecipitaed with anti-FLAG resin overnight to selectively co-
immunopreicipitate SAMHD1 binding proteins. When precipitants were 
blotted with anti-cyclin A2 antibody, the SAMHD1 wildtype and K405R 
showed no difference (Figure 50). This result suggests that SAMHD1 
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acetylation does not alter the binding of SAMHD1 and cyclin A2. However, 
additional research is needed to establish the relationship between SAMHD1 
acetylation and phosphorylation, as variety of molecular mechanisms may 
reside in between the two.
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Figure 39. Cell cycle profiles of SAMHD1-downregulated HeLa cells.
Cell cycle profiles of siCtrl or siSAMHD1 treated HeLa cells were 
determined by flow cytometry. Representative cell cycle profiles (top); the 
percentage of cells in each phase is presented as mean ±S.D. (n=3) (bottom)
*P<0.05; ***P<0.001; t- test
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Figure 40. Expression levels of cyclins in SAMHD1-down regulated 
HeLa cells. Lysates were extracted from siCtrl or siSAMHD1 treated HeLa 
cells and the levels of cyclin D1 and cyclin B1 were immunoblotted by 
corresponding antibodies.
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Figure 41. Cell cycle profiles of FLAG-SAMHD1 expressing stable A549 
cells. Cell cycle profiles of stable A549 cells expressing SAMHD1 wildtype, 
K405R or empty vector were determined by flow cytometry. Representative 
cell cycle profiles (top); the percentage of cells in each phase is presented as 
mean ±S.D. (n=3) (bottom) *P<0.05; **P<0.01;***P<0.001; t- test; N.S.; 
not significant
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Figure 42. Expression levels of cyclins in FLAG-SAMHD1 
overexpressing stable A549 cells. The levels of cyclin D1 and cyclin B1 
were immunoblotted in the lysates extracted from stable A549 cells 
expressing SAMHD1 wildtype, K405R or empty vector.
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Figure 43. PCNA expression of FLAG-SAMHD1 overexpressing stable 
Hep3B cells. Stable Hep3B cells expressing SAMHD1 wildtype, K405R or 
empty vector were serum-deprived for 48 h and were re-stimulated for 24 h, 
then the expressions of PCNA were monitored by confocal microscopy with 
immunofluorescence using the PCNA antibody. Hoechst was used for nuclei 
staining. PCNA, Proliferating cell nuclear antigen; Scale bar; 100 µm
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Figure 44. SAMHD1 acetylation levels during cell cycle progression of 
FLAG-SAMHD1 overexpressing stable A549 cells. FLAG-SAMHD1 
wildtype expressing stable A549 cells were synchronized to specific cell 
cycle phases using thymidine-double block method. SAMHD1 was 
precipitated and blotted with an anti-Lys-Ac antibody.
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Figure 45. SAMHD1 acetylation levels during cell cycle progression of 
FLAG-SAMHD1 overexpressing stable HeLa cells. FLAG-SAMHD1 
wildtype expressing stable HeLa cells were synchronized to specific cell 
cycle phases using thymidine-double block method. SAMHD1 was 
precipitated and blotted with an anti-Lys-Ac antibody.
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Figure 46. Expression levels of endogenous SAMHD1 during cell cycle 
progression of HeLa cells. HeLa cells were synchronized to specific cell 
cycle phases by thymidine double block method. The expression levels of 
SAMHD1 was assessed by western blotting.
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Figure 47. Expression levels of endogenous SAMHD1 during cell cycle 
progression of Hep3B cells. Hep3B cells were synchronized to specific cell 
cycle phases by thymidine double block method. The expression levels of 
SAMHD1 was assessed by western blotting.
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Figure 48. Expression levels of endogenous SAMHD1 during cell cycle 
progression of A549 cells. A549 cells were synchronized to specific cell 
cycle phases by thymidine double block method. The expression levels of 
SAMHD1 was assessed by western blotting.
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Figure 49. Expression levels of endogenous SAMHD1 during cell cycle 
progression of MCF7 cells. MCF7 cells were synchronized to specific cell 
cycle phases by thymidine double block method. The expression levels of 
SAMHD1 was assessed by western blotting.
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Figure 50. SAMHD1 acetylation does not alter SAMHD1-cyclin A2 
binding. FLAG-SAMHD1 wildtype or K405R were over expressed in 
HEK293T cells and immunoprecipitated lysates were blotted with anti-cyclin 
A2 antibody.
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6. SAMHD1 acetylation may play other undiscovered roles in various 
cell lines.
In an attempt to discover new roles of SAMHD1 acetylation, I have 
performed several additional experiments. 
(1) Physiological conditions of SAMHD1 acetylation in THP-1 cells
The antiviral activity of SAMHD1 is observed only in non-cycling immune 
cells such as dendritic cells, macrophages, monocytes, and quiescent CD4+ 
T cells. Since this activity is mediated by dNTPase activity of SAMHD1, I 
hypothesized that different acetylation status in cycling/non-cycling cells 
may have resulted in such phenomena. THP-1 cells were cultured in normal 
RPMI media or treated with PMA (Phorbol-12-Myristate-13-Acetate) for 
differentiation and stop cycling. To assess the acetylation levels of SAMHD1 
proteins from these cells, their cellular proteins were lysed, 
immunoprecipitated with Lys-Ac antibody and blotted with SAMHD1 
anitbody. PMA-treated THP-1 cells showed higher levels of acetylation 
compared to the control group (Figure 51A), which demonstrates that 
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differentiated THP-1 cells may exhibit stronger dNTPase activity. This result 
is opposite to the phosphorylation status of SAMHD1, as phosphorylation 
levels were reduced when PMA was treated (Cribier et al., 2013).
Type I interferon is known to be a negative regulator of the antiviral activity
of SAMHD1, reducing SAMHD1 T592 phosphorylation in various immune 
cells (Cribier et al., 2013). To investigate whether type I interferons also 
affect SAMHD1 acetylation, I have treated IFNβ-2a (Interferon β-2a) to 
THP-1 cells and checked SAMHD1 acetylation levels. The acetylation levels 
were reduced in IFNβ-2a treated cells (Figure 51B), opposite to the 
phosphorylation status reported in previous study (Cribier et al., 2013). 
Collectively, these results suggest the possibility that SAMHD1 acetylation 
may facilitate its antiviral activity, and that its functions may be opposite to 
SAMHD1 phosphorylation. 
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Figure 51. Physiological conditions of SAMHD1 acetylation in THP-1 
cells. (A) Endogenous SAMHD1 proteins were immunoprecipitated from 
PMA-treated THP-1 cells and blotted with Lys-Ac antibody. (B) 24h after 
IFNβ-2a treatment, endogenous SAMHD1 proteins were 
immunoprecipitated from THP-1 cells and blotted with Lys-Ac antibody.    
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(2) SAMHD1 and autophagy
Previous study has reported that cellular dNTP levels directly affects the 
induction of autophagy (Chen et al., 2014). Since SAMHD1 is a dNTPase 
and depletes cellular dNTPs, I hypothesized that SAMHD1 may play a role 
in autophagy induction. To investigate the function of SAMHD1, I 
downregulated SAMHD1 levels in HEK293T cells by transfection of 
specific siRNA. When SAMHD1 was silenced, the level of LC3B-II, a 
marker for autophagy induction, was increased (Figure 52A). This result 
demonstrates that SAMHD1 may inhibit the induction of autophagy. Next, to 
study the role of SAMHD1 when autophagy is induced, the siCtrl or 
siSAMHD1 treated HEK293T cells were treated with 4h of EBSS (Earle's 
Balanced Salt Solution) to induce autophagy. When compared to cells grown 
in normal DMEM, SAMHD1 expression levels were increased, indicating 
that autophagy may upregulate the induction of SAMHD1 protein (Figure 
52A). This result was also confirmed in HeLa cells (Figure 52B). The 
siSAMHD1-treated cells showed reduced LC3B-II levels compared to the 
siCtrl cells under EBSS treated condition, which suggests the possibility that 
SAMHD1 may enhance the autophagy status of the cell when autophagy is 
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induced; however this result conflicts with the previous results under normal 
condition. Considering the sophisticated effect of cellular dNTPs to the 
autophagy induction – low dNTP levels induce autophagy and continuous
autophagy results in low dNTP levels, a reciprocal regulation – it is 
suggested that the relationship between SAMHD1 and autophagy may also 
be complicated depending on the specific conditions. However these data 
shows that SAMHD1 does affect autophagy, therefore further studies are 
needed.
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Figure 52. Relationship between SAMHD1 and autophagy. (A) 
HEK293T cells were transfected with siCtrl or siSAMHD1 then subjected to 
normal DMEM or EBSS for 4 hrs. Cellular proteins were lysed, separated by 
SDS-PAGE and blotted with respective antibodies. (B) HeLa cells were 
cultured in either normal DMEM or EBSS for 24 hrs, and their cellular 
proteins were lysed and analyzed by western blot. C, Ctrl; S, SAMHD1
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(3) SAMHD1 acetylation and tight junction proteins
Tight junctions are the closely associated areas of two cells whose 
membranes join together forming a virtually impermeable barrier to fluid. 
Tight junction proteins such as ZO-1, occludin and E-cadherin are membrane 
proteins which cross-links to each other and forms the tight junctions.
Expression of such proteins in cancer cells are especially important for their 
loss may result in invasion and ultimately to the metastasis of cancer cells; 
therefore these proteins are widely-used as a metastasis marker. To 
investigate whether SAMHD1 acetylation can affect the levels of these 
proteins, Hep3B, HeLa, and A540 cells stably expressing FLAG-mock, 
SAMHD1, WT or K405R mutant were analyzed by western blot. In 
SAMHD1 WT expressing cells, expression levels of ZO-1 in HeLa cells and 
occludin in A549 cells were decreased, which were not observed in mutant 
expressing cells (Figure 53). Moreover, the levels of N-cadherin, a 
negative tight junction marker which promotes transendothelial migration of 
cancer cells, were increased in SAMHD1 WT expressing Hep3B cells and 
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not in mutant expressing cells (Figure 53). Altogether, these data suggest that 
SAMHD1 acetylation weakens the tight junction in cancer cells and that it 
may promote metastic behavior of these cells. 
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Figure 53. SAMHD1 acetylation alters the expression of junction 
proteins in various cancer cells. Stable Hep3B, HeLa, A549 cells 
expressing Flag-mock, SAMHD1 WT or K405R were lysed and their 
expression levels of junction proteins were analyzed by western-blot analysis.
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DISCUSSION
Since SAMHD1 has been first reported to have anti-HIV-1 activity, many 
studies have mainly concentrated on its mechanism of antiviral action. 
However, the expression of SAMHD1 is not only limited to immune cells 
but is observed ubiquitously in human organs, implying the existence of 
molecular mechanisms to regulate its enzymatic activity and its additional 
functions in non-immune cells. Here, I demonstrate a novel PTM of 
SAMHD1, its acetylation, and its roles in cancer cell proliferation (Figure 
54). SAMHD1 was acetylated by ARD1 at K405 residue, which directly 
enhanced its dNTPase activity in vitro. SAMHD1 acetylation level was 
found to be highest during G1 phase and facilitated G1/S transition, resulting 
in increased cell growth and colony forming ability in various cancer cells. I 
assume that the ability of SAMHD1 acetylation to promote G1-to-S phase is 
caused by its ability to deplete dNTPs, as K405R mutant, the acetylation-
blocked variant which shows decreased dNTPase activity, could not 
reproduce such phenomena. dNTP levels are known to have a direct effect on 
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control of cell cycle progression. Indeed, constitutively high dNTP 
concentration delays entry into S phase (Chabes and Stillman, 2007), and 
SAMHD1 is reported to promote S phase progression by lowering cellular 
dNTP pool critical for G1 checkpoint (Franzolin et al., 2013, Bonifati et al., 
2016). Hence, I suggest that the increased level of SAMHD1 acetylation 
during G1 phase contributes to low dNTP pool size sufficient for G1/S 
transition, which in turn promotes cancer cell proliferation (Figure 54). 
These findings broaden the understating of dNTP metabolism and cell cycle 
regulation, and provides SAMHD1 and its acetylation as a novel therapeutic 
target for cancer treatment. 
LC/MS-MS analysis revealed 2 acetylation site candidates; K405 and K580
(Figure 19). Among them, K580 was found to be a minor site as its 
acetylation levels showed little difference in the presence of ARD1 in vitro or 
in vivo (Figure 20, Figure 21), and its mutation did not alter its dNTPase 
activity in vitro (data not shown). Thus K580-acetylation may not play a 
meaningful role in ARD1-mediated SAMHD1 activation. However, I will 
not exclude the possibility that K580 residue-acetylation may exhibit other 
molecular mechanisms related to SAMHD1. 
SAMHD1 acetylation may contribute to its protein stability. While 
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overexpressing SAMHD1 wildtype and K405R mutant proteins in cell lines, 
I have noticed that SAMHD1 K405R expression levels tend to be lower than 
that of wildtypes (Figure 27, Figure 42). One hypothesis is that K405 
acetylation might alter the oligomerization of the protein and thus altering its 
protein-stability. Although this phenomenon was not evident in all the cell 
lines I have tested, I believe that further studies on this matter may find 
interesting mechanisms of SAMHD1 protein stability and degradation.
SAMHD1 acetylation may not only affect the cell cycle progression but 
also the anti-viral activity in non-cycling immune cells, for the ability of 
SAMHD1 to deplete dNTP pools is critical for limiting lentiviral replication 
in non-cycling immune cells (Goldstone et al., 2011, Lahouassa et al., 2012, 
White et al., 2013). The sole expression of SAMHD1 itself was insufficient 
to induce this effect in proliferating immune cells, implicating the existence 
of PTMs and/or a cofactor expressed only in non-proliferating cells (Baldauf 
et al., 2012, Descours et al., 2012). Here, I have discovered that SAMHD1 
acetylation mediated by ARD1 enhances its dNTPase function directly as 
acetylated SAMHD1 showed higher enzymatic activity over non-acetylated 
proteins and K405R mutants (Figure 2). Indeed, previous studies have 
reported that histone deacetylase inhibitors (HDACi) possess antiretroviral 
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activity that is SAMHD1‐dependent in macrophages; which suggests that 
protein acetylation related to SAMHD1 plays role in viral defense 
(Mlcochova et al., 2017). Therefore, further investigations on acetylation 
status in cycling/non-cycling myeloid cells are needed for deep 
understanding of the role of SAMHD1 acetylation in immune defense.
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Figure 54. Schematic for the mechanism of ARD1-mediated SAMHD1 
acetylation in cancer cell proliferation.
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CONCLUSION
SAMHD1 is a dNTPase that contributes to cell cycle progression and innate 
immunity. However, molecular mechanisms that directly regulates the 
dNTPase activity of SAMHD1 has been unexplored. Here, I suggest a novel 
post-translational modification of SAMHD1, acetylation, which regulates its 
dNTPase activity. SAMHD1 bound to and were acetylated at its well-
conserved K405 residue by ARD1, an acetyltransferase. Acetylated 
SAMHD1 showed higher dNTPase activity, whereas K405R mutants that 
cannot be acetylated did not. SAMHD1 was overexpressed in 
hepatocarcinoma tissues and its down regulation resulted in slow growth and 
less colony formation in cancer cell lines. SAMHD1 wildtype-
overexpressing stable cell lines grew faster and formed more colonies over 
mock or K405 mutant expressing cells in various cancer cell lines. These 
differential growth were caused by altered cell cycle, as SAMHD1 wildtype 
expressing cells showed increased G1/S transition over mock or K405R 
expressing cells. Moreover, SAMHD1 acetylation mainly occurred during 
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G1 phase, whereas endogenous expression levels of SAMHD1 did not show 
significant changes throughout the cell cycle progression. Altogether, ARD1-
mediated SAMHD1 enhances its dNTPase activity and contributes to cancer 
cell proliferation by facilitating G1/S transition. 
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국문초록
SAMHD1은 뉴클레오티드 3인산 분해능을 갖는 효소로써 이를
통해 면역세포에서 항레트로바이러스 효과를 나타낸다. 그러나
SAMHD1의 효소작용을 직접적으로 조절하는 분자기전은 밝혀진
바가 없다. 또한 SAMHD1이 면역세포뿐만 아니라 인체 내 다양
한 조직들에서 광범위하게 발현되므로 다른 세포에서도 특이적
기능을 가질 가능성이 크다. 본 연구자는 SAMHD1이 아세틸화됨
으로써 그 분해능이 증가하고 이를 통해 암세포 증식이 촉진됨을
연구하였다. SAMHD1은 아세틸화효소인 ARD1과 결합함으로써
라이신 405 잔기에 아세틸화가 일어났는데, 이러한 아세틸화가 in 
vitro 상에서 SAMHD1의 뉴클레오티드 3인산 분해능을 강화시킴
을 밝혔다. 아세틸화가 불가능하게 라이신 405를 아르기닌으로
치환시킨 변이형 SAMHD1 단백질은 아세틸화가 일어나지 않았
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으며 분해능도 강화되지 않았다. 선행 연구결과에 의하면 뉴클레
오티드 3인산의 양은 세포의 분열주기를 조절함으로써 세포증식
에 영향을 미친다. SAMHD1 아세틸화가 암세포의 증식에 어떤
영향을 미치는지 확인하게 위해 변이형 SAMHD1을 각종 암세포
에 과발현 시켰을 때 야생형보다 세포분열 및 군집생성능이 감소
됨을 확인하였다. 야생형과 변이형 SAMHD1을 과발현 하는 암세
포들의 각 세포분열시기별 조성을 분석한 결과 변이형에서는 G1
에서 S시기로의 전이가 감소되어있음을 확인하였다. SAMHD1 아
세틸화 정도를 세포분열시기 별로 확인해 본 결과 G1/G0 시기에
서 가장 많이 일어나는 것을 발견하였다. 그러나 SAMHD1의 발
현량 자체는 분열 시기별 변화가 미미하였으므로, SAMHD1의 양
이 아닌 아세틸화가 세포분열주기에 영향을 미친 것으로 생각된
다. 결론적으로, SAMHD1 아세틸화는 그 뉴클레오티드 3인산 분
해능을 강화함으로써 암세포의 증식을 촉진시킨다. 
주요어: SAMHD1, 아세틸화, ARD1, 3인산염 분해, 세포분열주기, 
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암세포 증식
